Welcome to our dedicated page for Minerva Neurosci news (Ticker: NERV), a resource for investors and traders seeking the latest updates and insights on Minerva Neurosci stock.
Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company developing product candidates for central nervous system (CNS) disorders, with a lead focus on roluperidone for negative symptoms of schizophrenia. The NERV news feed on Stock Titan aggregates company-issued updates and market-moving disclosures so readers can follow how Minerva’s clinical, regulatory and financing milestones evolve over time.
Recent news from Minerva highlights its ongoing interactions with the U.S. Food and Drug Administration (FDA) following a Complete Response Letter to its New Drug Application for roluperidone, as well as the agency’s requirement for a confirmatory Phase 3 trial. The company has released details about the planned trial design, including patient selection criteria, dosing, and the primary efficacy endpoint based on the PANSS Marder negative symptoms factor score.
Investors tracking NERV can also find announcements about Minerva’s private placement financing involving Series A Convertible Preferred Stock and warrants, which the company expects to use to fund the confirmatory Phase 3 study, NDA resubmission, and preparation for a potential U.S. commercial launch of roluperidone, if approved. Additional news items cover quarterly and annual financial results, changes in research and development and general and administrative expenses, and updates on the company’s cash position.
Governance and leadership developments appear in the news flow as well, including the appointment of new directors with schizophrenia clinical trial experience and a consulting agreement intended to support roluperidone’s late-stage development. For readers interested in CNS drug development, regulatory strategy, and biotech financing structures, the NERV news page provides a centralized view of Minerva’s public communications. Bookmark this page to review new press releases, earnings updates and material 8-K disclosures as they are reported.
Minerva Neurosciences (NASDAQ: NERV) reported Q2 2020 financial results, highlighting a net income of $29.5 million, or $0.75 per share, a turnaround from a loss of $12.5 million in the same period last year. The company recognized $41.2 million in collaborative revenue following its decision to opt out of the seltorexant agreement with Janssen. R&D expenses dropped to $5.8 million from $8.3 million year-over-year. However, the Phase 3 trial for roluperidone did not meet its primary endpoints, though some statistically significant improvements were observed.
Minerva Neurosciences (NASDAQ: NERV) announced a webcast on June 5, 2020, to present additional results from its Phase 3 trial focusing on negative symptoms of schizophrenia. This event replaces a previously scheduled session and will feature key opinion leaders who will discuss the findings. The company continues to develop roluperidone, a candidate for schizophrenia, alongside other compounds for insomnia and Parkinson's disease. Investors can participate via a conference call or listen to the live webcast, with an archived version available for 90 days.
Minerva Neurosciences announced that the Phase 3 trial for roluperidone to treat negative symptoms of schizophrenia did not meet its primary endpoint, which was the reduction in the PANSS Marder Negative Symptoms Factor Score. Both the 32 mg and 64 mg doses showed no significant difference from placebo at Week 12. However, the 64 mg dose demonstrated statistically significant effects at earlier time points, indicating potential efficacy. The drug was generally well tolerated, with adverse events comparable to placebo. The company plans to consult with the FDA regarding further development.
Summary not available.
Summary not available.